Search clinical trials for: DepoCyte

Total 87 results

Mundipharma Research Limited

Completed

Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.

Brain Metastases | Solid Tumour Neoplastic Meningitis

Austria, Germany
PETHEMA Foundation

Terminated

PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia (2009-009422-92)

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Completed

Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma

Lymphoma | Lymphoblastic Leukemia

Spain
Northern Italy Leukemia Group

Completed

Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Italy
Erasmus Medical Center

Completed

Autologous Tenocyte Implantation in Patients With Chronic Achilles Tendinopathy (ATI)

Tendinopathy | Achillodynia | Achilles Tendon Injury

Netherlands
Medical University of South Carolina

Terminated

A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma

Glioma | Astrocytoma | Brain Tumor | Glioblastoma Multiforme

United States
IRCCS San Raffaele
Mundipharma K.K.

Unknown

High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement (SCNSL1)

B-Cell Lymphomas

Italy
University of Washington
National Cancer Institute (NCI)

Completed

Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer

Stage IV Breast Cancer | Leptomeningeal Metastases | Recurrent Breast Cancer | Central Nervous System Metastases | Tumors Metastatic to Brain

United States
Nordic Lymphoma Group
Mundipharma Pte Ltd.; Amgen

Completed

CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis (CHIC)

Primary Disease

Denmark, Finland, Norway, Sweden
Centre Oscar Lambret

Completed

Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer (DEPOSEIN)

Breast Cancer | Leptomeningeal Metastases

France
Nordic Society for Pediatric Hematology and Oncology
Oulu University Hospital

Suspended

Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

Finland, Denmark, Sweden, Iceland, Norway
Duke University
Enzon Pharmaceuticals, Inc.

Terminated

DepoCyt for Active Lymphomatous or Leukemic Meningitis

Neoplastic Meningitis | Lymphoma, B Cell

United States
Beth Israel Deaconess Medical Center

Completed

Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
University of Florida
Novartis Pharmaceuticals

Withdrawn

iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)

Acute Myeloid Leukemia

United States
Goethe University

Completed

Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt

Adult Acute Lymphocytic Leukemia

Germany
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Charite University, Berlin, Germany

Unknown

High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas

Lymphoma, Non-Hodgkin

Germany
M.D. Anderson Cancer Center

Completed

Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

Leukemia | Myeloproliferative Diseases

United States
M.D. Anderson Cancer Center
Schering-Plough; Enzon Pharmaceuticals, Inc.

Terminated

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

Neoplastic Meningitis

United States
New York Medical College
Roswell Park Cancer Institute

Recruiting

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | CD20+ Lymphoblastic Lymphoma | Follicular Lymphoma, Grade III

United States
Kartos Therapeutics, Inc.

Terminated

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

United States, Spain, Korea, Republic of, Belgium, United Kingdom, Hungary, France, Germany, Israel, Australia, Italy, Poland
Dana-Farber Cancer Institute
Massachusetts General Hospital

Active, not recruiting

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
Eli Lilly and Company; High Impact Clinical Research Support Program

Completed

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia

United States
Massachusetts General Hospital
Boehringer Ingelheim

Withdrawn

Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

AML

United States
M.D. Anderson Cancer Center

Recruiting

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Leukemia

United States
Karyopharm Therapeutics Inc

Completed

Selinexor (KPT-330) in Older Patients With Relapsed AML (SOPRA)

Acute Myeloid Leukemia (AML)

Canada, United States, Israel, Netherlands, Denmark, Spain, France, Italy, United Kingdom, Germany, Poland
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Terminated

Depocyt® With Sorafenib in Neoplastic Meningitis

Neoplastic Meningitis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
M.D. Anderson Cancer Center
Jazz Pharmaceuticals

Withdrawn

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Hematologic Malignancy
University of Iowa

Terminated

Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Sanofi

Completed

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Leukemia

United States
M.D. Anderson Cancer Center

Completed

Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia

Leukemia

United States
Emory University

Withdrawn

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

Acute Myeloid Leukemia
M.D. Anderson Cancer Center

Completed

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Leukemia

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Schering-Plough

Completed

PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

Chronic Myeloid Leukemia

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Autologous Transplant in HIV Patients (BMT CTN 0803)

Lymphoma | HIV

United States
M.D. Anderson Cancer Center
Novartis

Completed

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid

United States
Michael Burke
Children's Hospitals and Clinics of Minnesota

Terminated

Epigenetic Reprogramming in Relapse AML

Leukemia, Acute Myeloid

United States
Kyowa Kirin, Inc.

Completed

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Adult T-cell Leukemia-Lymphoma

United States, United Kingdom, Belgium, France, Brazil, Peru
New York Medical College

Completed

Treatment for Advanced B-Cell Lymphoma (REBOOT)

Diffuse Large Cell Lymphoma | Burkitt's Lymphoma | High Grade B-cell Lymphoma

United States
Massachusetts General Hospital
Celgene

Unknown

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

AML

United States
M.D. Anderson Cancer Center

Recruiting

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Myelodysplastic Syndromes | Myeloproliferative Chronic Myelomonocytic Leukemia

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and other conditions

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
M.D. Anderson Cancer Center

Completed

Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Leukemia | AML | MDS | CML

United States
M.D. Anderson Cancer Center

Completed

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

Lymphoma

United States
Pacira Pharmaceuticals, Inc

Completed

DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor

Meningeal Neoplasms

United States, Canada
Washington University School of Medicine

Completed

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML (CLAG ATRA AML)

Leukemia, Myeloid, Acute

United States

Search clinical trials for: DepoCyte

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations